Abstract 58P
Background
There is an increasing incidence of RC in the young. Clinicopathologic features are not clearly established especially in the local Filipino population. Moreover, treatment challenges occur in this population. This study aims to describe the clinicopathologic profile and outcomes in patients diagnosed with RC in the young at the Southern Philippines Medical Center, Adult Cancer Institute.
Methods
All RC patients were reviewed from January 2018 to December 2021. A total of 548 RC patients were reviewed retrospectively.
Results
A total of 99 patients were identified (18%) as RC in the young. Majority were males (68%) and have a family history of cancer (72%). Mean tumor distance was 4.82+6.0 cm from the anal verge. All patients had adenocarcinoma histology with 9% having mucinous component and 1% with signet ring features. For tumor differentiation, 56% had moderately and 23% had poorly differentiated tumors. Most patients were diagnosed with locally advanced disease (55% St IIIB, 12% St IIIC) and 24% with distant metastasis. Mean CEA levels were elevated (preoperative 59.44ng/ml and post-operative 49.42ng/ml). Among non-metastatic disease, most stage II and stage III RC patients received neoadjuvant long course chemoradiation (LCCRT) then Surgery then adjuvant chemotherapy (AC) (52%). Most common AC used was Capecitabine-Oxaliplatin. At the time of analysis, 57.6% had no evidence of disease while 38.4% progressed or metastasized to distant organs. In the overall population of RC in the young, median overall survival was 21.3 months (mos). Survival rate at 12 mos was 60% and at 24 mos was 40%.
Conclusions
RC in the young Filipino patient presented more with lower lying rectal tumors, moderately to poorly differentiated histology, and more advanced disease at diagnosis. Survival appeared to be worse compared to historical data. Improved understanding of this specific subgroup is necessary for better treatment options and outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
48P - Long-term clinical outcomes after the second metastasectomy in patients (pts) with resected metastatic colorectal cancer (mCRC)
Presenter: Songji Choi
Session: Poster viewing 02
49P - Ramucirumab beyond progression plus TAS 102 in patients with advanced or metastatic adenocarcinoma of the stomach or the gastroesophageal junction, after treatment failure on a ramucirumab based therapy: Final results of the phase II RE-ExPEL study
Presenter: Thorsten Goetze
Session: Poster viewing 02
50P - Linear tumor regression of rectal cancer in daily MRI during preoperative chemoradiotherapy: An insight of tumor regression velocity for personalized cancer therapy
Presenter: Sea-Won Lee
Session: Poster viewing 02
51P - Efficacy and safety of sintilimab as first-line therapy in patients with microsatellite instability-high metastatic colorectal cancer: A real-world study
Presenter: Caiyun Nie
Session: Poster viewing 02
53P - Baseline PET/CT deep radiomics signature apply for identifying bevacizumab sensitivity of RAS-mutant colorectal cancer liver metastases patients
Presenter: Wenju Chang
Session: Poster viewing 02
54P - Efficacy of total neoadjuvant therapy (TNT) in rectal cancer: A meta-analysis of randomized controlled trials
Presenter: Yakup Ergün
Session: Poster viewing 02
55P - Biodegradable and biocompatible 3D-printed scaffolds loaded with chemotherapy drugs: A new horizon for treatment of colon cancer with diffuse intraperitoneal metastasis
Presenter: Amirhosein Kefayat
Session: Poster viewing 02
56P - Clinico-pathological profile of adolescent and young adult colorectal cancer patients: Multicentre collaborative registry data from India
Presenter: Soumya Surath Panda
Session: Poster viewing 02